358 related articles for article (PubMed ID: 35442453)
1. Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant.
Eick-Cost AA; Ying S; Wells N
JAMA Netw Open; 2022 Apr; 5(4):e228071. PubMed ID: 35442453
[TBL] [Abstract][Full Text] [Related]
2. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
[TBL] [Abstract][Full Text] [Related]
3. Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study.
Bohnert AS; Kumbier K; Rowneki M; Gupta A; Bajema K; Hynes DM; Viglianti E; O'Hare AM; Osborne T; Boyko EJ; Young-Xu Y; Iwashyna TJ; Maciejewski M; Schildhouse R; Dimcheff D; Ioannou GN
BMJ; 2023 May; 381():e074521. PubMed ID: 37220941
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study.
Castelli JM; Rearte A; Olszevicki S; Voto C; Del Valle Juarez M; Pesce M; Iovane AN; Paz M; Chaparro ME; Buyayisqui MP; Markiewicz MB; Landoni M; Giovacchini CM; Vizzotti C
BMJ; 2022 Nov; 379():e073070. PubMed ID: 36450402
[TBL] [Abstract][Full Text] [Related]
5. Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance.
Britton A; Fleming-Dutra KE; Shang N; Smith ZR; Dorji T; Derado G; Accorsi EK; Ajani UA; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Mar; 327(11):1032-1041. PubMed ID: 35157002
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of various COVID-19 vaccine regimens among 10.4 million patients from the National COVID Cohort Collaborative during Pre-Delta to Omicron periods - United States, 11 December 2020 to 30 June 2022.
Fu Y; Wu K; Wang Z; Yang H; Chen Y; Wu L; Yanagihara R; Hedges JR; Wang H; Deng Y;
Vaccine; 2023 Oct; 41(42):6339-6349. PubMed ID: 37741761
[TBL] [Abstract][Full Text] [Related]
7. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
[TBL] [Abstract][Full Text] [Related]
8. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting.
Rane MS; Robertson MM; Kulkarni SG; Frogel D; Gainus C; Nash D
Vaccine; 2023 Jan; 41(4):989-998. PubMed ID: 36588007
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years.
Tartof SY; Frankland TB; Slezak JM; Puzniak L; Hong V; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM
JAMA Netw Open; 2022 Aug; 5(8):e2225162. PubMed ID: 35921109
[TBL] [Abstract][Full Text] [Related]
11. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines.
Kelly JD; Leonard S; Hoggatt KJ; Boscardin WJ; Lum EN; Moss-Vazquez TA; Andino R; Wong JK; Byers A; Bravata DM; Tien PC; Keyhani S
JAMA; 2022 Oct; 328(14):1427-1437. PubMed ID: 36156706
[TBL] [Abstract][Full Text] [Related]
13. Trends in COVID-19 Vaccine Administration and Effectiveness Through October 2021.
Winkelman TNA; Rai NK; Bodurtha PJ; Chamberlain AM; DeSilva M; Jeruzal J; Johnson SG; Kharbanda A; Klyn N; Mink PJ; Muscoplat M; Waring S; Yu Y; Drawz PE
JAMA Netw Open; 2022 Mar; 5(3):e225018. PubMed ID: 35357452
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
Thompson MG; Stenehjem E; Grannis S; Ball SW; Naleway AL; Ong TC; DeSilva MB; Natarajan K; Bozio CH; Lewis N; Dascomb K; Dixon BE; Birch RJ; Irving SA; Rao S; Kharbanda E; Han J; Reynolds S; Goddard K; Grisel N; Fadel WF; Levy ME; Ferdinands J; Fireman B; Arndorfer J; Valvi NR; Rowley EA; Patel P; Zerbo O; Griggs EP; Porter RM; Demarco M; Blanton L; Steffens A; Zhuang Y; Olson N; Barron M; Shifflett P; Schrag SJ; Verani JR; Fry A; Gaglani M; Azziz-Baumgartner E; Klein NP
N Engl J Med; 2021 Oct; 385(15):1355-1371. PubMed ID: 34496194
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans.
Dickerman BA; Gerlovin H; Madenci AL; Kurgansky KE; Ferolito BR; Figueroa Muñiz MJ; Gagnon DR; Gaziano JM; Cho K; Casas JP; Hernán MA
N Engl J Med; 2022 Jan; 386(2):105-115. PubMed ID: 34942066
[TBL] [Abstract][Full Text] [Related]
17. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ
JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data.
Bello-Chavolla OY; Antonio-Villa NE; Valdés-Ferrer SI; Fermín-Martínez CA; Fernández-Chirino L; Vargas-Vázquez A; Ramírez-García D; Mancilla-Galindo J; Kammar-García A; Ávila-Funes JA; Zúñiga-Gil CH; García-Grimshaw M; Ceballos-Liceaga SE; Carbajal-Sandoval G; Montes-González JA; Zaragoza-Jiménez CA; García-Rodríguez G; Cortés-Alcalá R; Reyes-Terán G; López-Gatell H; Gutiérrez-Robledo LM
Int J Infect Dis; 2023 Apr; 129():188-196. PubMed ID: 36775188
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant.
Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L
Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006
[TBL] [Abstract][Full Text] [Related]
20. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States.
Schrag SJ; Verani JR; Dixon BE; Page JM; Butterfield KA; Gaglani M; Vazquez-Benitez G; Zerbo O; Natarajan K; Ong TC; Lazariu V; Rao S; Beaver R; Ellington SR; Klein NP; Irving SA; Grannis SJ; Kiduko S; Barron MA; Midturi J; Dickerson M; Lewis N; Stockwell MS; Stenehjem E; Fadel WF; Link-Gelles R; Murthy K; Goddard K; Grisel N; Valvi NR; Fireman B; Arndorfer J; Konatham D; Ball S; Thompson MG; Naleway AL
JAMA Netw Open; 2022 Sep; 5(9):e2233273. PubMed ID: 36156146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
